Abstract
High levels of IL-6 were found in 50% of 114 patients with primary ovarian cancer. IL-6 sensitivity was lower than that of CA 125, and the combination of both assays did not increase the sensitivity of CA 125 alone. However, elevated IL-6 serum levels were correlated with a poor prognosis since patients with low IL-6 levels had a better survival than patients with high IL-6 levels (P = 0.0009). Multivariate analysis revealed that IL-6 positivity has an independent value.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scambia, G., Testa, U., Benedetti Panici, P. et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71, 354–356 (1995). https://doi.org/10.1038/bjc.1995.71
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.71
This article is cited by
-
The beneficial role of SIRT1 activator on chemo- and radiosensitization of breast cancer cells in response to IL-6
Molecular Biology Reports (2020)
-
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth
Oncogene (2019)
-
The association between the inflammatory potential of diet and risk of developing, and survival following, a diagnosis of ovarian cancer
European Journal of Nutrition (2019)
-
Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients
BMC Genomics (2017)
-
Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis
Current Oncology Reports (2016)
